Celluma’s Light Therapy Innovation and Low-Touch Therapies Loved by Facialists Around the World
Anaheim, California – July 15, 2021 – BioPhotas, Inc., the global market leader in therapeutic LED Light Therapy devises announced five new aesthetic industry awards for its continued focus on product innovation for its Celluma SERIES of devises. For the fourth year in a row, Celluma was voted “Best LED Devise” by the Associated Skin Care Professionals (ASCP) organisation for its ability to effectively treat a variety of skin conditions in a user-friendly design.
Celluma Light Therapy was recognised by Les Nouvelles Esthetiques & Spa Magazine with two best product awards. The Celluma POD received the LNE winner’s seal as Best Face Handheld. Boasting the same efficacy and 3-in-1 versatility of Celluma’s larger canopy-style panels, the POD is the only handheld Light Therapy devise on the market FDA-cleared to treat acne, pain and ageing.
The Celluma PRO, the Company’s flagship model, won for Best Light Therapy devise. The PRO is a versatile, 3-in-1 panel that treats acne, wrinkles and pain. Its unique shape-taking design facilitates close positioning to the treatment area, a patented feature which greatly optimises clinical outcomes.
Dermascope Magazine also recognised Celluma devises with two Aesthetician’s Choice Awards. The Celluma PRO continues to shine as the most awarded LED panel on the market and the Celluma DELUX was the Aesthetician’s Choice for a full-body devise. The DELUX is the first portable full-body devise that carries all the regulatory credentials as the other Celluma SERIES models, eliminating the exorbitant cost and space requirements of LED beds.
“BioPhotas is the recognised leader in the LED Light Therapy space, not because we say so, but because the readers of international aesthetic journals say so,” said Patrick Johnson, President and CEO of BioPhotas and the inventor of the Celluma. “We are proud that the Celluma SERIES of Light Therapy devises began its winning ways in 2015, shortly after commercial introduction to the aesthetics market, and has accumulated more than 40 industry awards since then.”
Mr. Johnson also shared some additional exciting news, “Having just celebrated the 10th anniversary of BioPhotas, it is only appropriate that we receive our 10th indication-for-use clearance from the FDA. The Celluma SERIES now has more regulatory credentials than any other LED devise in the world and is legally registered for sale in 78 countries around the globe.”
To view the complete Celluma SERIES of devises, visit https://international.celluma.com/.
About BioPhotas, Inc.
In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions. For more information about the Celluma, please visit www.celluma.com.